12-Apr-2022 - PharmAI GmbH

A free AI tool to quickly determine which protein labeling strategy works best for molecular interaction measurements

NanoTemper Technologies and PharmAI launch Proto

NanoTemper Technologies, in partnership with PharmAI, announced the launch of Proto, a free AI-based web application that reveals the best labeling strategy to help scientists more efficiently measure molecular interactions, a process that’s necessary to discover and develop new drugs. Proto is one the first commercial applications using the AlphaFold protein structure database that was made freely accessible by EMBL-EBI and DeepMind, an Alphabet company.

Scientists in drug discovery need to detect and measure how well proteins bind to molecules, which requires labeling, usually with the aid of a dye. If the wrong labeling strategy is chosen, it leads to time-consuming and costly investigations.

"Proto makes use of more than 700,000 protein structures from AlphaFold or from the RCSB Protein Data Bank to suggest the appropriate dye for binding measurements," explains Christina Wolf, Data Scientist at NanoTemper. "This makes binding measurements more efficient and reliable, and it gives scientists additional confidence in their results."

This novel labeling prediction is another important step towards optimizing experiments in the field of biotechnology and the pharmaceutical industry with the help of artificial intelligence. "We want to help optimize research into diseases and therapeutics — that’s why we are making the tool free of charge," says Philipp Baaske, Co-CEO of NanoTemper. “There are numerous rare diseases that are currently unprofitable for large pharmaceutical companies to study. The possibilities offered by AI-based software could enable smaller laboratories to enter the field of drug research in the future and make new therapies possible with their work, benefiting us all,” adds Joachim Haupt, CEO of PharmAI.

Facts, background information, dossiers
More about PharmAI
  • News

    NanoTemper Technologies teams up with PharmAI to help researchers spot game-changing drug candidates from millions of possibilities

    NanoTemper Technologies and PharmAI combine competencies to develop biophysical tools that remove costly and time-consuming guesswork from large datasets. PharmAI announced a partnership with NanoTemper Technologies, the most innovative producer of biophysical characterization devices. Toge ... more

    Looking for a needle in a haystack

    The goal: Identify new drugs for Covid-19 therapy in the fastest possible way, conduct clinical tests and win the battle against the virus. The method: A large-scale research competition that screens billions of molecules in order to find those blocking interactions on SARS-CoV-2, identifyi ... more

  • Companies

    PharmAI GmbH

    Our disruptive software technology identifies drug candidates based on the geometry of protein binding sites and their drug-target interactions, paving new ways to explore the drug-target space at a ground-breaking level of precision. more

More about NanoTemper Technologies